Physician profile
William Tung
NPI 1528594058
$1,580.31
in general payments reported to CMS, 2019-2025
23 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $55.34 · 2024: $633 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $166.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $156.15 | 2024 | Gi Genius |
| Takeda Pharmaceuticals U.S.A., INC. | $130.39 | 2024-2025 | Entyvio |
| Ucb, INC. | $120.00 | 2025 | Nayzilam |
| Harmony Biosciences LLC | $116.35 | 2024-2025 | |
| Genzyme Corporation | $113.80 | 2024-2025 | |
| Abbvie INC. | $112.74 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $111.84 | 2025 | Voquezna |
| Janssen Biotech, INC. | $99.44 | 2024-2025 | Tremfya |
| Genentech USA, INC. | $94.66 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $57.61 | 2025 | Rexulti |
| Livanova USA, INC. | $45.64 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Regeneron Healthcare Solutions, INC. | $41.94 | 2024 | Dupixent |
| Qol Medical, LLC | $39.84 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $26.03 | 2025 | Iqirvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $24.84 | 2025 | |
| Merck Sharp & Dohme LLC | $24.63 | 2024 | Dificid |
| Biocon Biologics INC | $21.57 | 2025 | Yesintek |
| Ardelyx, INC. | $19.72 | 2025 | Ibsrela |
| Pfizer INC. | $16.87 | 2025 | |
| Ferring Pharmaceuticals INC. | $14.25 | 2025 | Rebyota |
| Celltrion USA INC. | $13.52 | 2025 | Vegzelma |
| Impel Pharmaceuticals LLC | $11.65 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.